Debjit Chattopadhyay

facebook_page
twitter_page

Last quote by Debjit Chattopadhyay

If Sarepta does get the approval the stock is going to be meaningfully higher, probably in the $35 to $45 range. Else the stock could be in the $5 range.
May 23 2016
Debjit Chattopadhyay has been quoted 3 times. The one recent article where Debjit Chattopadhyay has been quoted is Sarepta shares sink as FDA staff stay sour on muscle drug. Most recently, Debjit Chattopadhyay was quoted as having said, “BioMarin's drug is dead. Eteplirsen is now dead. There is nothing in DMD for the foreseeable future.”.
Automatically powered byStoryzy

Quotes by Debjit Chattopadhyay

<
facebook_page
twitter_page